Does the media prefer TNGX or ELAN?

In the previous week, Elanco Animal Health had 1 more articles in the media than Tango Therapeutics. MarketBeat recorded 9 mentions for Elanco Animal Health and 8 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 1.41 beat Elanco Animal Health's score of 0.72 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AXSM or TNGX?

In the previous week, Axsome Therapeutics had 3 more articles in the media than Tango Therapeutics. MarketBeat recorded 11 mentions for Axsome Therapeutics and 8 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 1.41 beat Axsome Therapeutics' score of 0.77 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ARWR or TNGX?

In the previous week, Arrowhead Pharmaceuticals had 15 more articles in the media than Tango Therapeutics. MarketBeat recorded 23 mentions for Arrowhead Pharmaceuticals and 8 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 1.41 beat Arrowhead Pharmaceuticals' score of 1.07 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 10 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TNGX or ABVX more profitable?

Tango Therapeutics' return on equity of -41.54% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Tango Therapeutics N/A -41.54% -33.44% Abivax N/A -99.02% -70.26%

Does the media refer more to TNGX or ABVX?

In the previous week, Abivax had 5 more articles in the media than Tango Therapeutics. MarketBeat recorded 13 mentions for Abivax and 8 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 1.41 beat Abivax's score of 1.41 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 12 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer KRYS or TNGX?

In the previous week, Krystal Biotech had 8 more articles in the media than Tango Therapeutics. MarketBeat recorded 16 mentions for Krystal Biotech and 8 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 1.41 beat Krystal Biotech's score of 1.17 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 12 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tango Therapeutics (TNGX) Competitors

$27.18 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$27.16 -0.02 (-0.06%)

As of 07/31/2026 07:34 PM Eastern

Compare

TNGX vs. ELAN, AXSM, ARWR, ABVX, and KRYS

Should you buy Tango Therapeutics stock or one of its competitors? MarketBeat compares Tango Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tango Therapeutics include Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), Arrowhead Pharmaceuticals (ARWR), Abivax (ABVX), and Krystal Biotech (KRYS).

How does Tango Therapeutics compare to Elanco Animal Health?

Tango Therapeutics (NASDAQ:TNGX) and Elanco Animal Health (NYSE:ELAN) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

Tango Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-41.54%	-33.44%
Elanco Animal Health	-4.95%	7.42%	3.66%

Tango Therapeutics currently has a consensus target price of $42.15, indicating a potential upside of 55.09%. Elanco Animal Health has a consensus target price of $28.73, indicating a potential upside of 8.72%. Given Tango Therapeutics' higher possible upside, equities research analysts plainly believe Tango Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Tango Therapeutics has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	63.03	-$101.59M	-$0.83	N/A
Elanco Animal Health	$4.89B	2.70	-$232M	-$0.50	N/A

In the previous week, Elanco Animal Health had 1 more articles in the media than Tango Therapeutics. MarketBeat recorded 9 mentions for Elanco Animal Health and 8 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 1.41 beat Elanco Animal Health's score of 0.72 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tango Therapeutics has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market.

Summary

Elanco Animal Health beats Tango Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Tango Therapeutics compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Tango Therapeutics has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	17.57	-$183.17M	-$3.73	N/A
Tango Therapeutics	$62.38M	63.03	-$101.59M	-$0.83	N/A

Axsome Therapeutics has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market.

Tango Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Tango Therapeutics' return on equity of -41.54% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Tango Therapeutics	N/A	-41.54%	-33.44%

In the previous week, Axsome Therapeutics had 3 more articles in the media than Tango Therapeutics. MarketBeat recorded 11 mentions for Axsome Therapeutics and 8 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 1.41 beat Axsome Therapeutics' score of 0.77 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Axsome Therapeutics presently has a consensus target price of $261.29, indicating a potential upside of 19.86%. Tango Therapeutics has a consensus target price of $42.15, indicating a potential upside of 55.09%. Given Tango Therapeutics' higher probable upside, analysts plainly believe Tango Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	2 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.91
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Tango Therapeutics beats Axsome Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Tango Therapeutics compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Arrowhead Pharmaceuticals has higher revenue and earnings than Tango Therapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	14.38	-$1.63M	-$2.15	N/A
Tango Therapeutics	$62.38M	63.03	-$101.59M	-$0.83	N/A

Arrowhead Pharmaceuticals has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

Arrowhead Pharmaceuticals currently has a consensus target price of $96.92, suggesting a potential upside of 14.49%. Tango Therapeutics has a consensus target price of $42.15, suggesting a potential upside of 55.09%. Given Tango Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tango Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Tango Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Tango Therapeutics' return on equity of -41.54% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
Tango Therapeutics	N/A	-41.54%	-33.44%

In the previous week, Arrowhead Pharmaceuticals had 15 more articles in the media than Tango Therapeutics. MarketBeat recorded 23 mentions for Arrowhead Pharmaceuticals and 8 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 1.41 beat Arrowhead Pharmaceuticals' score of 1.07 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	10 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tango Therapeutics beats Arrowhead Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Tango Therapeutics compare to Abivax?

Tango Therapeutics (NASDAQ:TNGX) and Abivax (NASDAQ:ABVX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Tango Therapeutics has higher revenue and earnings than Abivax. Tango Therapeutics is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	63.03	-$101.59M	-$0.83	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Tango Therapeutics has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market. Comparatively, Abivax has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market.

In the previous week, Abivax had 5 more articles in the media than Tango Therapeutics. MarketBeat recorded 13 mentions for Abivax and 8 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 1.41 beat Abivax's score of 1.41 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	12 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tango Therapeutics' return on equity of -41.54% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-41.54%	-33.44%
Abivax	N/A	-99.02%	-70.26%

Tango Therapeutics currently has a consensus price target of $42.15, suggesting a potential upside of 55.09%. Abivax has a consensus price target of $156.50, suggesting a potential upside of 25.28%. Given Tango Therapeutics' higher probable upside, equities analysts plainly believe Tango Therapeutics is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Tango Therapeutics beats Abivax on 10 of the 13 factors compared between the two stocks.

How does Tango Therapeutics compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

In the previous week, Krystal Biotech had 8 more articles in the media than Tango Therapeutics. MarketBeat recorded 16 mentions for Krystal Biotech and 8 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 1.41 beat Krystal Biotech's score of 1.17 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	12 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech has a net margin of 53.92% compared to Tango Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Tango Therapeutics	N/A	-41.54%	-33.44%

Krystal Biotech has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market.

Krystal Biotech presently has a consensus price target of $360.67, indicating a potential upside of 5.73%. Tango Therapeutics has a consensus price target of $42.15, indicating a potential upside of 55.09%. Given Tango Therapeutics' higher probable upside, analysts plainly believe Tango Therapeutics is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Krystal Biotech has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	25.84	$204.83M	$7.48	45.60
Tango Therapeutics	$62.38M	63.03	-$101.59M	-$0.83	N/A

Summary

Krystal Biotech beats Tango Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Tango Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNGX vs. The Competition

Export

Metric	Tango Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.93B	$3.54B	$6.86B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-32.75	7.38	282.30	24.66
Price / Sales	63.03	1,201.52	564.98	76.51
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	10.58	16.78	10.92	6.07
Net Income	-$101.59M	-$12.56M	$3.49B	$347.99M
7 Day Performance	1.72%	-1.79%	-0.64%	-0.44%
1 Month Performance	-7.74%	-8.41%	-5.24%	-4.81%
1 Year Performance	316.23%	48.37%	61.98%	18.61%

Tango Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNGX Tango Therapeutics	2.5698 of 5 stars	$27.18 flat	$42.15 +55.1%	+316.2%	$3.93B	$62.38M	N/A	90	News Coverage Positive News Upcoming Earnings
ELAN Elanco Animal Health	2.9495 of 5 stars	$25.66 +1.0%	$28.73 +12.0%	+91.5%	$12.82B	$4.89B	N/A	9,400	Positive News Upcoming Earnings Analyst Upgrade
AXSM Axsome Therapeutics	3.3115 of 5 stars	$233.14 -2.2%	$261.48 +12.2%	+111.6%	$12.00B	$638.50M	N/A	380	Upcoming Earnings Analyst Forecast Gap Up
ARWR Arrowhead Pharmaceuticals	2.33 of 5 stars	$83.44 -2.4%	$95.08 +14.0%	+431.4%	$11.75B	$829.45M	N/A	400	Positive News Upcoming Earnings Gap Up
ABVX Abivax	3.9263 of 5 stars	$124.57 -2.7%	$156.50 +25.6%	+73.6%	$10.86B	N/A	N/A	61	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNGX) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tango Therapeutics (TNGX) Competitors

TNGX vs. ELAN, AXSM, ARWR, ABVX, and KRYS

How does Tango Therapeutics compare to Elanco Animal Health?

Summary

How does Tango Therapeutics compare to Axsome Therapeutics?

Summary

How does Tango Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Tango Therapeutics compare to Abivax?

Summary

How does Tango Therapeutics compare to Krystal Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNGX vs. The Competition

Tango Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tango Therapeutics (TNGX) Competitors

TNGX vs. ELAN, AXSM, ARWR, ABVX, and KRYS

How does Tango Therapeutics compare to Elanco Animal Health?

Is TNGX or ELAN more profitable?

Do analysts recommend TNGX or ELAN?

Do insiders & institutionals have more ownership in TNGX or ELAN?

Which has better earnings and valuation, TNGX or ELAN?

Does the media prefer TNGX or ELAN?

Which has more volatility & risk, TNGX or ELAN?

Summary

How does Tango Therapeutics compare to Axsome Therapeutics?

Do institutionals & insiders believe in AXSM or TNGX?

Which has better earnings & valuation, AXSM or TNGX?

Which has more risk & volatility, AXSM or TNGX?

Is AXSM or TNGX more profitable?

Does the media refer more to AXSM or TNGX?

Do analysts prefer AXSM or TNGX?

Summary

How does Tango Therapeutics compare to Arrowhead Pharmaceuticals?

Do institutionals & insiders hold more shares of ARWR or TNGX?

Which has higher valuation & earnings, ARWR or TNGX?

Which has more volatility and risk, ARWR or TNGX?

Do analysts prefer ARWR or TNGX?

Is ARWR or TNGX more profitable?

Does the media favor ARWR or TNGX?

Summary

How does Tango Therapeutics compare to Abivax?

Which has higher valuation & earnings, TNGX or ABVX?

Do insiders and institutionals have more ownership in TNGX or ABVX?

Which has more risk & volatility, TNGX or ABVX?

Does the media refer more to TNGX or ABVX?

Is TNGX or ABVX more profitable?

Do analysts recommend TNGX or ABVX?

Summary

How does Tango Therapeutics compare to Krystal Biotech?

Does the media prefer KRYS or TNGX?

Is KRYS or TNGX more profitable?

Which has more volatility & risk, KRYS or TNGX?

Do analysts rate KRYS or TNGX?

Do insiders and institutionals believe in KRYS or TNGX?

Which has better earnings & valuation, KRYS or TNGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNGX vs. The Competition

Tango Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools